Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study) : A Double-Blind, Randomized Clinical Trial
المؤلفون المشاركون
Sarrafzadegan, Nizal
Joharimoghadam, Adel
Boshtam, Maryam
Roohafza, Hamidreza
Shokouh, Pedram
Golabchi, Allahyar
Sadeghi, Masoumeh
المصدر
العدد
المجلد 2013، العدد 2013 (31 ديسمبر/كانون الأول 2013)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2013-04-18
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
العلوم الطبيعية والحياتية (متداخلة التخصصات)
الأحياء
الملخص EN
The present trial aimed to investigate the effects of pioglitazone on the serum level of asymmetric dimethylarginine (ADMA), a marker of endothelial function, and some indices of inflammation and glucose and lipid metabolism in nondiabetic metabolic syndrome patients.
104 eligible participants (57% female; age between 20 and 70) were enrolled in a double-blind placebo-controlled trial and were randomized to receive either pioglitazone (uptitrated to 30 mg/day) or matching placebo for 24 weeks.
Participants were clinically examined and a blood sample was obtained at baseline and at the end of the trial.
Pioglitazone significantly improved C-reactive protein level irrespective of changes in insulin sensitivity.
Compared with the placebo group, alanine and aspartate transaminases were decreased and high-density lipoprotein cholesterol was increased after treatment with pioglitazone.
A considerably greater weight gain was also recorded in the intervention group.
We failed to observe any significant changes in serum ADMA in either group and between groups with and without adjustment for age, sex, and components of the metabolic syndrome.
In a nutshell, pioglitazone seems to have positive effects on lipid profile, liver transaminases, and systemic inflammation.
However, its previously demonstrated endothelial function-improving properties do not seem to be mediated by ADMA.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Shokouh, Pedram& Joharimoghadam, Adel& Roohafza, Hamidreza& Sadeghi, Masoumeh& Golabchi, Allahyar& Boshtam, Maryam…[et al.]. 2013. Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study) : A Double-Blind, Randomized Clinical Trial. PPAR Research،Vol. 2013, no. 2013, pp.1-9.
https://search.emarefa.net/detail/BIM-465577
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Shokouh, Pedram…[et al.]. Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study) : A Double-Blind, Randomized Clinical Trial. PPAR Research No. 2013 (2013), pp.1-9.
https://search.emarefa.net/detail/BIM-465577
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Shokouh, Pedram& Joharimoghadam, Adel& Roohafza, Hamidreza& Sadeghi, Masoumeh& Golabchi, Allahyar& Boshtam, Maryam…[et al.]. Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study) : A Double-Blind, Randomized Clinical Trial. PPAR Research. 2013. Vol. 2013, no. 2013, pp.1-9.
https://search.emarefa.net/detail/BIM-465577
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-465577
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر